

# Steven R A Simoens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6946870/publications.pdf>

Version: 2024-02-01

131  
papers

4,534  
citations

117625

34  
h-index

123424

61  
g-index

132  
all docs

132  
docs citations

132  
times ranked

4639  
citing authors

#	ARTICLE	IF	CITATIONS
1	How much do the public sector and the private sector contribute to biopharmaceutical R&D?. Drug Discovery Today, 2022, 27, 939-945.	6.4	6
2	Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. BioDrugs, 2022, 36, 217-229.	4.6	15
3	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Frontiers in Medicine, 2022, 9, 820755.	2.6	16
4	Emerging Insights into European Markets of Biologics, Including Biosimilars. Pharmaceuticals, 2022, 15, 615.	3.8	1
5	Critical Reflections on Reimbursement and Access of Advanced Therapies. Frontiers in Pharmacology, 2022, 13, .	3.5	6
6	How do biosimilars sustain value, affordability, and access to oncology care?. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 327-329.	1.4	9
7	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. Haemophilia, 2021, 27, 129-136.	2.1	27
8	Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discovery Today, 2021, 26, 399-415.	6.4	20
9	A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. BioDrugs, 2021, 35, 75-87.	4.6	11
10	A health economic guide to market access of biosimilars. Expert Opinion on Biological Therapy, 2021, 21, 9-17.	3.1	23
11	Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives. Patient, 2021, 14, 119-128.	2.7	23
12	Oral healthcare delivery in institutionalised older people: A health economic evaluation. Gerodontology, 2021, , .	2.0	3
13	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs, 2021, 13, 1868078.	5.2	17
14	Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals, 2021, 14, 117.	3.8	30
15	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 527-540.	1.4	48
16	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. Frontiers in Medicine, 2021, 8, 595797.	2.6	8
17	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Frontiers in Pharmacology, 2021, 12, 644187.	3.5	14
18	Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study. Pharmaceuticals, 2021, 14, 450.	3.8	4

#	ARTICLE	IF	CITATIONS
19	Off-Patent Biologicals and Biosimilars Tendering in Europe – A Proposal towards More Sustainable Practices. <i>Pharmaceuticals</i> , 2021, 14, 499.	3.8	18
20	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 53.	2.4	7
21	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. <i>Haemophilia</i> , 2021, 27, 957-966.	2.1	14
22	Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets. <i>BioDrugs</i> , 2021, 35, 89-101.	4.6	20
23	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. <i>Frontiers in Pharmacology</i> , 2021, 12, 789640.	3.5	6
24	Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 155-175.	2.1	25
25	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 5-16.	2.1	31
26	Tendering and biosimilars: what role for value-added services?. <i>Journal of Market Access &amp; Health Policy</i> , 2020, 8, 1705120.	1.5	15
27	Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. <i>BioDrugs</i> , 2020, 34, 159-170.	4.6	75
28	Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review. <i>Pharmaceuticals</i> , 2020, 13, 400.	3.8	8
29	Integrative Review of Managed Entry Agreements: Chances and Limitations. <i>Pharmacoeconomics</i> , 2020, 38, 1165-1185.	3.3	25
30	European Stakeholder Learnings Regarding Biosimilars: Part II – Improving Biosimilar Use in Clinical Practice. <i>BioDrugs</i> , 2020, 34, 797-808.	4.6	33
31	European Stakeholder Learnings Regarding Biosimilars: Part I – Improving Biosimilar Understanding and Adoption. <i>BioDrugs</i> , 2020, 34, 783-796.	4.6	39
32	Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. <i>Pharmaceuticals</i> , 2020, 13, 324.	3.8	20
33	Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. <i>Frontiers in Pharmacology</i> , 2020, 11, 594446.	3.5	21
34	A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8001.	2.6	5
35	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 734-755.	4.7	86
36	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	10.9	58

#	ARTICLE	IF	CITATIONS
37	Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. <i>Journal of Market Access &amp; Health Policy</i> , 2020, 8, 1739509.	1.5	8
38	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , 2019, 121, 199-210.	6.4	48
39	Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US. <i>Frontiers in Pharmacology</i> , 2019, 10, 1009.	3.5	16
40	Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 189.	3.0	36
41	What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 895-902.	2.1	3
42	Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. <i>Patient</i> , 2019, 12, 513-526.	2.7	24
43	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2 – Biosimilar and Originator Etanercept in the Outpatient Setting. <i>BioDrugs</i> , 2019, 33, 299-306.	4.6	16
44	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1 – Biosimilar and Originator Infliximab in the Hospital Setting. <i>BioDrugs</i> , 2019, 33, 285-297.	4.6	23
45	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1395.	3.5	48
46	Nanomedicines: The magic bullets reaching their target?. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 128, 73-80.	4.0	73
47	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019, 24, 57-68.	6.4	69
48	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. <i>GaBI Journal</i> , 2019, 8, 49-70.	0.3	31
49	Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. <i>Value in Health</i> , 2018, 21, 493-500.	0.3	75
50	Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice. <i>Frontiers in Medicine</i> , 2018, 5, 285.	2.6	13
51	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	2.7	102
52	Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries. <i>Frontiers in Pharmacology</i> , 2018, 9, 1108.	3.5	7
53	The necessity for a European definition of drug shortages. <i>International Journal of Pharmacy Practice</i> , 2018, 26, 289-290.	0.6	3
54	Outrageous prices of orphan drugs: a call for collaboration. <i>Lancet</i> , The, 2018, 392, 791-794.	13.7	132

#	ARTICLE	IF	CITATIONS
55	How to realize the potential of off-patent biologicals and biosimilars in Europe? Guidance to policymakers. <i>GaBI Journal</i> , 2018, 7, 70-74.	0.3	8
56	Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 1047-1062.	3.3	34
57	Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. <i>Frontiers in Pharmacology</i> , 2017, 8, 171.	3.5	107
58	Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. <i>Frontiers in Pharmacology</i> , 2017, 8, 322.	3.5	21
59	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , 2017, 8, 497.	3.5	34
60	The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. <i>Frontiers in Pharmacology</i> , 2017, 8, 314.	3.5	80
61	Policies for biosimilar uptake in Europe: An overview. <i>PLoS ONE</i> , 2017, 12, e0190147.	2.5	153
62	Potential Solutions for Sustaining the Costs of Cancer Drugs. <i>European Oncology and Haematology</i> , 2017, 13, 102.	0.0	13
63	What Happens when the Cost of Cancer Care Becomes Unsustainable?. <i>European Oncology and Haematology</i> , 2017, 13, 108.	0.0	10
64	Can we Continue to Afford Access to Cancer Treatment?. <i>European Oncology and Haematology</i> , 2017, 13, 114.	0.0	18
65	Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs. <i>Frontiers in Pharmacology</i> , 2016, 7, 144.	3.5	7
66	Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. <i>Frontiers in Pharmacology</i> , 2016, 7, 193.	3.5	65
67	Off-label use of orphan medicinal products: a Belgian qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 144.	2.7	12
68	Toward a European definition for a drug shortage: a qualitative study. <i>Frontiers in Pharmacology</i> , 2015, 6, 253.	3.5	44
69	Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, 1320-1329.e3.	1.3	745
70	Are orphan drug companies the pick of the pharmaceutical industry?. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 10-10.	46.4	10
71	Market access of cancer drugs in European countries: improving resource allocation. <i>Targeted Oncology</i> , 2014, 9, 95-110.	3.6	33
72	Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study. <i>Pharmacoeconomics</i> , 2014, 32, 681-691.	3.3	64

#	ARTICLE	IF	CITATIONS
73	Cost-Effectiveness Assessment of Orphan Drugs. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 1-3.	2.1	60
74	Terminal patients in Belgian nursing homes: a cost analysis. <i>European Journal of Health Economics</i> , 2013, 14, 407-413.	2.8	8
75	Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 198.	2.7	104
76	Generic Atorvastatin, the Belgian Statin Market and the Cost-Effectiveness of Statin Therapy. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 49-60.	2.6	9
77	Personalizing health care: feasibility and future implications. <i>BMC Medicine</i> , 2013, 11, 179.	5.5	81
78	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , 2013, 4, 39.	3.5	75
79	Pharmaco-economic aspects of Sipuleucel-T. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 506-508.	3.3	7
80	Biosimilars and market access: a question of comparability and costs?. <i>Targeted Oncology</i> , 2012, 7, 227-231.	3.6	25
81	Orphan Drugs for Rare Diseases. <i>Drugs</i> , 2012, 72, 1437-1443.	10.9	50
82	Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 74.	2.7	127
83	Orphan Drugs for Rare Diseases: Grounds for Special Status. <i>Drug Development Research</i> , 2012, 73, 115-119.	2.9	14
84	From generic to biosimilar drugs: why take an innovative pace?. <i>Farmeconomia E Percorsi Terapeutici</i> , 2012, 13, 21-27.	0.1	1
85	Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 24-26.	0.6	11
86	Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?. <i>Health Policy</i> , 2011, 101, 146-152.	3.0	68
87	Public health and prevention in Europe: is it cost-effective?. <i>Journal of Pharmaceutical Health Services Research</i> , 2011, 2, 151-155.	0.6	1
88	Biosimilar medicines and cost-effectiveness. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 29.	1.9	86
89	Pricing and reimbursement of orphan drugs: the need for more transparency. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 42.	2.7	184
90	Consumption Patterns and In Vitro Resistance of <i>Streptococcus pneumoniae</i> to Fluoroquinolones. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3051-3053.	3.2	13

#	ARTICLE	IF	CITATIONS
91	Factors Affecting the Cost Effectiveness of Antibiotics. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-6.	1.6	15
92	Endometriosis Cost Assessment (the EndoCost Study): A Cost-of-Illness Study Protocol. <i>Gynecologic and Obstetric Investigation</i> , 2011, 71, 170-176.	1.6	74
93	The Use of Intravenous Immunoglobulins in Belgium. <i>International Archives of Allergy and Immunology</i> , 2011, 154, 173-176.	2.1	5
94	Non-health-care costs associated with endometriosis. <i>Human Reproduction</i> , 2011, 26, 2363-2367.	0.9	20
95	Budget impact analysis of adjunctive therapy with lacosamide for partial-onset epileptic seizures in Belgium. <i>Journal of Medical Economics</i> , 2011, 14, 299-304.	2.1	4
96	Detecting pre-diabetes and the role of the pharmacist. <i>Pharmacy Practice</i> , 2011, 9, 88-92.	1.5	4
97	Economic evaluation of pharmacy practice: research informing policy. <i>International Journal of Pharmacy Practice</i> , 2010, 16, 337-338.	0.6	4
98	Generic Medicine Pricing Policies in Europe: Current Status and Impact. <i>Pharmaceuticals</i> , 2010, 3, 471-481.	3.8	47
99	Treatment of primary immunodeficiency with Kiovig®: a literature review. <i>Advances in Therapy</i> , 2010, 27, 142-149.	2.9	2
100	The Costs of Treating Terminal Patients. <i>Journal of Pain and Symptom Management</i> , 2010, 40, 436-448.	1.2	35
101	Health Technology Assessment and Economic Evaluation across Jurisdictions. <i>Value in Health</i> , 2010, 13, 857-859.	0.3	5
102	How to assess the value of medicines?. <i>Frontiers in Pharmacology</i> , 2010, 1, 115.	3.5	37
103	Health Economics of Antibiotics. <i>Pharmaceuticals</i> , 2010, 3, 1348-1359.	3.8	4
104	Health Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria. <i>International Journal of Environmental Research and Public Health</i> , 2010, 7, 1835-1840.	2.6	17
105	Use of Economic Evaluation in Decision Making. <i>Drugs</i> , 2010, 70, 1917-1926.	10.9	6
106	Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 309-315.	1.4	10
107	Health Economic Assessment: A Methodological Primer. <i>International Journal of Environmental Research and Public Health</i> , 2009, 6, 2950-2966.	2.6	73
108	Ostomy appliance prices in Europe. <i>Journal of Medical Economics</i> , 2009, 12, 17-24.	2.1	1

#	ARTICLE	IF	CITATIONS
109	Analysis of Drug Authentication at the Point of Dispensing in Belgian and Greek Community Pharmacies. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1701-1706.	1.9	11
110	International comparison of orthotic brace prices. <i>European Journal of Health Economics</i> , 2009, 10, 149-155.	2.8	2
111	Patient experiences of over-the-counter medicine purchases in Flemish community pharmacies. <i>International Journal of Clinical Pharmacy</i> , 2009, 31, 450-457.	1.4	32
112	Developing Competitive and Sustainable Polish Generic Medicines Market. <i>Croatian Medical Journal</i> , 2009, 50, 440-448.	0.7	20
113	Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. <i>Current Medical Research and Opinion</i> , 2009, 25, 2447-2457.	1.9	9
114	Pharmacoeconomics of immunoglobulins in primary immunodeficiency. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 375-386.	1.4	16
115	Which barriers prevent the efficient use of resources in medical device sectors?. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 209-217.	2.1	8
116	Health economics of market access for biopharmaceuticals and biosimilars. <i>Journal of Medical Economics</i> , 2009, 12, 211-218.	2.1	17
117	Cardiovascular drug use prior to diagnosis of diabetes: a pilot study in community pharmacy. <i>International Journal of Pharmacy Practice</i> , 2009, 17, 127-9.	0.6	1
118	Cardiovascular drug use prior to diagnosis of diabetes: a pilot study in community pharmacy. <i>International Journal of Pharmacy Practice</i> , 2009, 17, 127-129.	0.6	0
119	Trends in generic prescribing and dispensing in Europe. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 497-503.	3.1	29
120	Reforming the Belgian market for orthotic braces: What can we learn from the international experience?. <i>Health Policy</i> , 2008, 86, 195-203.	3.0	4
121	Health economics of medical devices: opportunities and challenges. <i>Journal of Medical Economics</i> , 2008, 11, 713-717.	2.1	6
122	A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1735-1744.	1.8	8
123	Do tariffs and prices correspond with costs? A case study of orthotic braces. <i>Journal of Medical Economics</i> , 2008, 11, 245-254.	2.1	2
124	Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 633-648.	1.8	17
125	Economic aspects of antimicrobial therapy of acute exacerbations of COPD. <i>Respiratory Medicine</i> , 2007, 101, 15-26.	2.9	12
126	Drawing on international experience to reform the Belgian market for ostomy appliances. <i>Health Policy</i> , 2007, 80, 273-280.	3.0	2



#	ARTICLE	IF	CITATIONS
127	International comparison of generic medicine prices. <i>Current Medical Research and Opinion</i> , 2007, 23, 2647-2654.	1.9	70
128	Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDs. <i>International Journal of Clinical Pharmacy</i> , 2006, 28, 309-317.	1.4	2
129	Management of drug interactions with beta-blockers: continuing education has a short-term impact. <i>Pharmacy Practice</i> , 2006, 4, 143-50.	1.5	0
130	Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycin. <i>Pharmacy Practice</i> , 2006, 4, 68-73.	1.5	4
131	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2